Eur Rev Med Pharmacol Sci 2021; 25 (21): 6443-6443

DOI: 10.26355/eurrev_202111_27130

The safety profile of probiotic VSL#3®. A meta-analysis of safety data from double-blind, randomized, placebo-controlled clinical trials

V. Panetta, A. Bacchieri, S. Papetti, E. De Stefani, P. Navarra

L’altrastatistica S.r.l., for GB Pharma Services & Consulting S.r.l, Rome, Italy


The article “The safety profile of probiotic VSL#3®. A meta-analysis of safety data from
double-blind, randomized, placebo-controlled clinical trials”, by V. Panetta, A. Bacchieri, S. Papetti, E. De Stefani, P. Navarra, published in Eur Rev Med Pharmacol Sci 2020; 24 (2): 963-973–DOI: 10.26355/eurrev_202001_20082–PMID: 32017005, has been retracted based on commentary received from a new set of reviewers.  The authors will be able to resubmit a new article addressing the reviewers’ comments for the Journal’s consideration.

The Publisher apologizes for any inconvenience this may cause.

The safety profile of probiotic VSL#3®. A meta-analysis of safety data from double-blind, randomized, placebo-controlled clinical trials

Free PDF Download

To cite this article

V. Panetta, A. Bacchieri, S. Papetti, E. De Stefani, P. Navarra
The safety profile of probiotic VSL#3®. A meta-analysis of safety data from double-blind, randomized, placebo-controlled clinical trials

Eur Rev Med Pharmacol Sci
Year: 2021
Vol. 25 - N. 21
Pages: 6443-6443
DOI: 10.26355/eurrev_202111_27130